DNL 975
Alternative Names: DNL-975Latest Information Update: 28 May 2021
Price :
$50 *
At a glance
- Originator Denali Therapeutics Inc
- Class Anti-inflammatories; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Crohn's disease